Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

IMFINZI: resectable Bladder Cancer (neoadjuvant) after prior therapy

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

• IMFINZI in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent IMFINZI as adjuvant treatment following radical cystectomy, is indicated for the treatment of adult patients with muscle invasive bladder cancer (MIBC). 1. 7 Gastric or gastroesophageal junction adeno carcinoma IMFINZI in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) as neoadjuvant and adjuvant treatment, followed by single-agent IMFINZI, is indicated for the treatment of adult patients with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).

Broader topic: Bladder Cancer

Source population
Not part of this definition
Disease extent
Not part of this definition
Treatment line
neoadjuvant
Stage
Not part of this definition
Resectability
resectable
Biomarkers, prior therapy and derivation
molecular
    prior therapy
    1. class
      following radical cystectomy
      status
      required
    derivation status
    source-attested
    derivation note
    Scoped from the FDA approved indication for IMFINZI (product label). Only dimensions stated in that wording are part of this definition.
    source wording
    • IMFINZI in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent IMFINZI as adjuvant treatment following radical cystectomy, is indicated for the treatment of adult patients with muscle invasive bladder cancer (MIBC). 1. 7 Gastric or gastroesophageal junction adeno carcinoma IMFINZI in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) as neoadjuvant and adjuvant treatment, followed by single-agent IMFINZI, is indicated for the treatment of adult patients with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).

    Study evidence for this setting

    0 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

    No linked study matches these filters. This is a source-coverage gap, not evidence that there are no treatment options.

    Source relationships and population-mapping limitations
    bindings
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice